You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Comparison of median doses (interquartile range) in the six months prior to and six months after inflammatory disease therapy initiation

From: Claims for disease-modifying therapy by Alberta non-insured health benefits clients

  Acetaminophen NSAIDsa Opioidsb Corticosteroidsc
DMARDs Only (Incident to database after 2002) n = 456 Pre: 180.6 mg (88.9–500) Post: 277.8 mg (88.9–666.7) (p = 0.7) Pre: 455.6 mg (216.7–866.7) Post: 547.9 mg (233.3–1067.7) (p = 0.02) Pre: 3.3 mg (1.1–9.4) Post: 3.4 mg (0.8–14.0) (p = 0.08) Pre: 6.2 mg (1.8–11.4) Post: 5.3 mg (2.1–13.7) (p = 0.7)
Biologic Usersd n = 229 Pre: 277.8 mg (166.7–833.3) Post: 277.8 mg (83.3–555.6) (p = 0.5) Pre: 600.0 mg (305.3–1200.0) Post: 633.3 mg (300.0–1333.3) (p = 0.2) Pre: 18.0 mg (5.0–56.1) Post: 22.3 mg (7.4–58.4) (p = 0.04) Pre: 5.0 mg (1.75–10.0) Post: 5.8 mg (2.1–10.6) (p = 0.02)
  1. amg of ibuprofen equivalent
  2. bmg of morphine equivalent
  3. cmg of prednisone equivalent
  4. dIncludes patients with data available for 6 months prior to and following biologic initiation